RBC Capital Downgrades Sage Therapeutics to Underperform, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has downgraded Sage Therapeutics from Sector Perform to Underperform and reduced its price target from $10 to $4.
October 04, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has downgraded Sage Therapeutics to Underperform and significantly lowered its price target from $10 to $4, indicating a negative outlook.
The downgrade from Sector Perform to Underperform by RBC Capital suggests a negative outlook for Sage Therapeutics. The significant reduction in the price target from $10 to $4 indicates a lack of confidence in the company's near-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100